Interoperability That Pays Off: Turning Data Exchange Into ROI

Muhammed Chebli, vice president of product, interoperability at NextGen Healthcare, joins HealthLeaders editor Jay Asser to break down how to translate interoperability from an IT initiative into measurable business value.

Evy Olson, vice president of nursing programs at Vizient, joins HealthLeaders editor Jay Asser to discuss how evidence-based nurse residency and leadership transition programs are a workforce necessity that help healthcare organizations address turnover, strengthen leadership pipelines, and sustain care quality.

Cancer screening is evolving beyond a single-organ approach to an approach that evaluates multiple organs throughout the entirety of the body with a simple blood test. In this episode, Dr. Michelle Beidelschies shares how Cancerguard can help health systems detect more cancers earlier, reduce late-stage diagnoses, and improve outcomes. We explore the clinical, operational, and financial implications of adopting multi-cancer early detection testing at scale. Information presented is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice. The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.

Dr. Tomasz Beer, MD, chief medical officer at Exact Sciences, joins HealthLeaders for a discussion on the clinical research behind Cancerguard tests and how they enable health systems to detect multiple deadly cancers early, streamline diagnostic workflows, and deliver proactive, value-based care. Information presented is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice. The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.

Get insights on digital transformation and the future of clinician-centered AI with Ed Lee, MD, MPH, chief medical officer at Nabla.

Jason Spring, vice president of Vizient Member Networks, joins HealthLeaders editor Jay Asser to discuss how the role of healthcare boards is shifting amid rapid industry change, and how effective governance can shape safer, stronger organizations.

David Harding, senior vice president, pipeline product management at Exact Sciences, joins HealthLeaders for a discussion on how to help health system leaders understand the foundation of Multi-Cancer Early Detection (MCED) and how it can impact cancer diagnosis, drive innovation and improve patient outcomes. Information presented is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice.

Chase McGrath, vice president of product at Aspirion, joins HealthLeaders editor Jay Asser to guide revenue cycle leaders through the strategic adoption of AI for denials management, offering both the why and the how behind successful implementation.

Jodi Eisenberg, associate vice president of Vizient Member Networks, joins HealthLeaders editor Jay Asser to discuss how today’s chief quality executives are moving from compliance stewards to strategic leaders shaping the future of healthcare.

Advice for healthcare leaders, clinicians, and quality professionals to understand the rapidly evolving landscape of clinical quality measurement and its growing impact on patient care, compliance, and reimbursement.